Format

Send to

Choose Destination
Blood. 2019 Feb 7;133(6):566-575. doi: 10.1182/blood-2018-07-865527. Epub 2018 Nov 29.

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

Author information

1
Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany.
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
3
Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, MA.
4
Harvard Medical School, Boston, MA.
5
Division of Hematology & Oncology, Chao Family Comprehensive Center Center, UC Irvine Health, Orange, CA.
6
LifeMine Therapeutics, Cambridge, MA; and.
7
Broad Institute of Harvard and MIT, Cambridge, MA.

Abstract

There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the response rate to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy. We characterized the mitochondrial apoptosis pathway in cell lines and patient-derived xenograft (PDX) models of TCL and assessed the in vitro efficacy of BH3 mimetics, including the BCL2 inhibitor venetoclax, the BCL2/BCL-xL inhibitor navitoclax, and the novel MCL1 inhibitor AZD5991. The abundance of antiapoptotic BCL2 family members based on immunoblotting or RNA transcript levels correlated poorly with the activity of BH3 mimetics. In contrast, the functional approach BH3 profiling reliably predicted sensitivity to BH3 mimetics in vitro and in vivo. We used BH3 profiling to select TCL PDX that were dependent on MCL1. Mice xenografted with these PDX and treated with AZD5991 had markedly improved survival. The combination of AZD5991 and CHOP achieved synergy based on survival improvement beyond a mathematical "sum of benefits" model. Thus, MCL1 inhibition is a promising strategy as both a single agent and in combination with chemotherapy for patients with TCL and functional dependence on MCL1.

PMID:
30498064
PMCID:
PMC6367646
[Available on 2020-02-07]
DOI:
10.1182/blood-2018-07-865527

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center